Release Therapeutics SA Sustained-Release Implant Capsule

The European Patent Office published patent EP4013381A1 granting Release Therapeutics SA and co-applicants exclusive rights to an implantable capsule technology. The patent covers sustained-release drug delivery mechanisms with IPC classifications in A61K 9/00, A61F 2/02, A61K 35/12, and A61L 27/38, indicating applications in pharmaceutical preparations and medical devices. The patent is designated across 27 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

For pharmaceutical companies, medical device manufacturers, and healthcare providers, this patent establishes intellectual property protection for sustained-release implant technology in the European market. Entities developing similar drug delivery systems should assess freedom-to-operate implications and potential licensing opportunities with the patent holders.